1. Introduction

The regulation of vaccine development and emergency approval pathways in Morocco is an important part of public health law, pharmaceutical regulation, biotechnology governance and administrative law.

Vaccines are biological medicinal products designed to prevent infectious diseases by stimulating the immune system. Their development involves scientific research, laboratory testing, preclinical studies, clinical trials, manufacturing, quality control, regulatory authorization and post-marketing safety surveillance.

Morocco has developed a pharmaceutical regulatory framework intended to ensure that vaccines are safe, effective and manufactured according to internationally recognized standards.

The COVID-19 pandemic highlighted the importance of:

Accelerated vaccine development.

Emergency clinical trial procedures.

Regulatory assessment of vaccine safety and effectiveness.

Government responsibility for vaccine-related injuries.

Domestic vaccine manufacturing capacity.

International cooperation in vaccine research and distribution.

The principal legislation includes Law No. 17-04 on the Code of Medicines and Pharmacy, Law No. 28-13 on the Protection of Persons Participating in Biomedical Research, and the 2024 pharmaceutical reforms.

An important distinction must be made between emergency authorization of a clinical trial and emergency authorization to market or administer a vaccine. They are legally different procedures.

2. Constitutional and Legislative Framework

A. Constitution of Morocco, 2011

The Moroccan Constitution provides the broader foundation for public health regulation.

Article 31 recognizes the state's responsibility to facilitate access to healthcare and medical treatment.

This constitutional responsibility supports government measures concerning:

Vaccine development.

Prevention of infectious diseases.

Access to immunization.

Protection of public health.

Regulation of pharmaceutical products.

Article 154 also establishes principles governing public services, including transparency, accountability and quality.

Consequently, vaccine regulatory authorities must exercise their powers consistently with constitutional principles and applicable legislation.

B. Law No. 17-04: Code of Medicines and Pharmacy

Law No. 17-04, promulgated by Dahir No. 1-06-151 of 22 November 2006, is the principal pharmaceutical legislation.

It establishes the legal framework for the manufacture, importation, distribution and marketing of medicinal products.

Article 8 is particularly important. It requires appropriate prior experimentation demonstrating:

The effectiveness of the medicinal product.

Its safety under normal conditions of use.

Its therapeutic value.

Compliance with applicable quality requirements.

Manufacturers and importers must also demonstrate that appropriate manufacturing and quality-control methods are available.

These requirements apply to vaccines as medicinal products.

The ordinary marketing authorization process therefore requires scientific and pharmaceutical evidence rather than relying exclusively on a manufacturer's declaration.

sante.gov.ma+2

C. Decree No. 2-14-841

Decree No. 2-14-841 establishes implementing rules concerning marketing authorization for medicinal products intended for human use.

Its regulatory significance includes:

Submission of authorization applications.

Examination of pharmaceutical documentation.

Evaluation of product quality.

Assessment of manufacturing procedures.

Regulatory decisions concerning marketing authorization.

A vaccine manufacturer must satisfy the applicable authorization requirements before placing the vaccine on the Moroccan market.

D. Law No. 28-13 of 2015: Biomedical Research

Law No. 28-13 is particularly relevant to vaccine research and clinical trials.

It regulates research involving human participants and establishes protections for individuals participating in biomedical investigations.

Important provisions include:

Article 27 is particularly important because authorization of biomedical research requires favourable ethical review and scientific justification, including consideration of preclinical evidence and foreseeable risks.

Article 34 establishes the sponsor's responsibility for injury to research participants where the necessary causal connection is established.

Article 37 requires immediate reporting of serious adverse events potentially attributable to the research.

Thus, emergency circumstances do not eliminate the legal protection owed to clinical-trial participants.

sante.gov.ma+1

3. Institutional Regulatory Authorities

A. Ministry of Health and Social Protection

The Ministry is responsible for national health policy and plays an important role in:

Vaccine policy development.

Public immunization programmes.

Health emergency coordination.

Vaccine procurement.

Public health surveillance.

Administration of applicable regulatory powers.

B. Moroccan Agency for Medicines and Health Products (AMMPS)

The Moroccan Agency for Medicines and Health Products is an important institution in pharmaceutical regulation.

Its responsibilities include regulatory oversight of medicinal products and relevant quality-control functions.

Law No. 10-22 established the Agency.

The 2024 reforms also assigned the Agency a central role in official vaccine batch-release procedures.

C. Regional Biomedical Research Ethics Committees

Under Law No. 28-13, regional committees assess biomedical research proposals from an ethical perspective.

Their responsibilities include examining:

Participant safety.

Informed consent.

Scientific justification.

Research protocols.

Potential risks.

Protection of vulnerable participants.

D. Institut Pasteur du Maroc

The Institut Pasteur du Maroc has an important role in vaccine research, biological products and vaccine manufacturing activities.

Its Serum and Vaccine Centre has participated in vaccine production and pharmaceutical operations, including Morocco's COVID-19 vaccine manufacturing initiative.

Institut Pasteur du Maroc+1

4. Legal Regulation of Vaccine Development

Vaccine development involves several legally regulated stages.

A. Scientific Research and Discovery

The initial stage involves identifying pathogens and developing vaccine candidates.

Research may involve:

Viral and bacterial investigations.

Genetic engineering.

Recombinant DNA technology.

mRNA technology.

Protein-subunit vaccines.

Viral-vector platforms.

Immunological investigations.

Researchers and institutions must comply with applicable biomedical research, biosafety, laboratory and ethical requirements.

Research involving human participants is subject to Law No. 28-13.

B. Preclinical Testing

Before human clinical trials, vaccine candidates undergo appropriate laboratory and animal investigations.

The purpose is to examine:

Toxicity.

Immunogenicity.

Biological activity.

Potential adverse reactions.

Dosage considerations.

Preliminary safety characteristics.

Preclinical information is important when the competent authority evaluates whether human testing is scientifically justified.

C. Clinical Trials

Clinical trials generally involve three principal stages.

Phase I – Initial safety assessment

A relatively small group of participants is studied to assess initial safety, tolerability and dosage.

Phase II – Immunogenicity and dosage

Researchers investigate immune responses, dosage schedules and additional safety information in a larger participant group.

Phase III – Efficacy and broader safety

Larger clinical studies evaluate protective efficacy and identify less common adverse reactions.

Under Moroccan law, the applicable biomedical research authorization and ethical review requirements must be satisfied.

The sponsor must maintain safety records, report serious adverse events and comply with the approved research protocol.

D. Manufacturing and Quality Control

Vaccine manufacturers must comply with applicable pharmaceutical manufacturing standards.

Important areas include:

Good Manufacturing Practices (GMP).

Sterility and contamination controls.

Biological potency.

Stability testing.

Batch consistency.

Packaging and labelling.

Cold-chain requirements.

A vaccine that demonstrates efficacy in clinical trials cannot automatically be treated as compliant with manufacturing and quality requirements.

Both scientific effectiveness and manufacturing quality are essential.

5. Emergency Vaccine Approval Pathways in Morocco

Emergency vaccine approval is particularly important during epidemics, pandemics and other serious public health emergencies.

An emergency pathway seeks to accelerate regulatory procedures without abandoning scientific assessment, ethical protection or safety monitoring.

A. Emergency clinical-trial procedures

Morocco has taken steps to establish accelerated procedures for clinical research during health emergencies.

A significant recent development occurred on 23 April 2026, when the AMMPS announced publication of its Guidelines on the Conduct of Clinical Trials in Emergency Situations.

According to the Agency, these guidelines address:

Eligibility for emergency procedures.

Accelerated examination of applications.

Specific decision-making timelines.

Safety monitoring.

Reporting of safety information.

Protection of research participants.

Scientific and ethical requirements.

This development is important because it provides a more structured framework for conducting biomedical research during health emergencies.

However, it is essential to understand that accelerated approval of a clinical trial does not itself authorize commercial marketing or general administration of the vaccine.

AMMPS+1

B. Emergency Marketing Authorization

Emergency marketing authorization concerns permission to place a vaccine on the market or make it available for use in circumstances requiring an accelerated public health response.

It must be distinguished from ordinary clinical-trial authorization.

The Moroccan pharmaceutical framework provides for marketing authorization under Law No. 17-04 and its implementing regulations.

The available legal materials establish the ordinary authorization requirements and emergency clinical-trial guidance. They do not, by themselves, establish a comprehensive, independent statutory emergency-use authorization system equivalent to every country's EUA model.

Therefore, an emergency vaccine decision must be examined by identifying its precise legal instrument, competent authority, scientific assessment and conditions of use.

Relevant considerations include:

Available clinical evidence.

Safety and efficacy data.

Manufacturing quality.

Urgency of the public health situation.

Availability of alternative vaccines.

International regulatory assessments.

Risk-management measures.

Continuing pharmacovigilance.

C. Conditional Authorization and Continuing Evidence

Where a vaccine is considered for use before all long-term evidence is available, the regulatory authority must distinguish between established evidence and remaining uncertainty.

Potential regulatory safeguards include:

Additional clinical investigations.

Periodic safety reports.

Further efficacy studies.

Restrictions on eligible populations.

Updated product information.

Suspension or withdrawal where serious safety concerns arise.

These are important regulatory safeguards; they should not be interpreted as proof that Morocco has adopted every form of conditional authorization available in foreign jurisdictions.

6. COVID-19 and Morocco's Emergency Vaccine Programme

The COVID-19 pandemic provides an important practical example of Moroccan vaccine regulation.

Morocco introduced a national vaccination programme and used vaccines including Sinopharm and AstraZeneca.

The government had to address several regulatory challenges:

First, vaccine procurement: The government needed to secure adequate supplies through international cooperation and procurement arrangements.

Second, scientific evaluation: Vaccine safety and efficacy information had to be assessed before use.

Third, manufacturing capacity: Morocco sought to strengthen domestic vaccine production and reduce dependence on foreign suppliers.

Fourth, public safety: Adverse reactions required monitoring and appropriate medical responses.

Fifth, administrative responsibility: Questions arose concerning compensation for individuals who suffered alleged vaccine-related injuries.

Morocco's Sinopharm manufacturing initiative

The Institut Pasteur du Maroc's Serum and Vaccine Centre participated in the national COVID-19 vaccine manufacturing initiative.

Its responsibilities included:

Registration-related pharmaceutical procedures.

Technology transfer.

Analytical testing.

Manufacturing supervision.

Quality control.

Batch release activities.

Pharmacovigilance and effectiveness monitoring.

This initiative illustrates the relationship between vaccine sovereignty, technology transfer and pharmaceutical regulation.

Institut Pasteur du Maroc+1

7. The 2024 Vaccine Regulatory Reform: Official Batch Release

One of the most significant developments in Moroccan vaccine regulation is Decree-Law No. 2-24-728 of 27 September 2024.

It amended Law No. 17-04 by introducing a dedicated legal framework for the official release of vaccine and serum batches intended for human use.

The reform introduced Articles 17-1 to 17-4.

The central principle is that every relevant locally manufactured or imported vaccine batch must undergo official batch-release procedures before being placed on the market.

The reform also introduced Article 150-1, establishing a fine of MAD 100,000 to MAD 1 million for violating the first paragraph of Article 17-2. The fine doubles in cases of repetition.

An important qualification is that the UNICEF exemption concerns the batch-release certificate under Article 17-3. It should not be interpreted as a general exemption from all other applicable pharmaceutical and safety requirements.

The accompanying Decree No. 2-24-729 identifies the AMMPS as the competent national authority for this process.

These reforms strengthen regulatory oversight of vaccines independently of the initial marketing authorization.

SGG+1

8. Post-Marketing Surveillance and Pharmacovigilance

Approval is not the final stage of vaccine regulation.

A vaccine may produce adverse reactions that were not identified during clinical trials because clinical trials cannot always detect very rare events.

Therefore, post-marketing surveillance is essential.

The principal regulatory concerns include:

A. Adverse-event reporting

Healthcare professionals and relevant institutions must follow applicable reporting requirements for suspected adverse reactions.

B. Signal detection

Authorities examine safety reports to identify patterns that may indicate previously unrecognized risks.

C. Risk-benefit assessment

Regulators must assess whether the vaccine's protective benefits continue to justify its potential risks.

D. Product information

New safety information may require changes to warnings, contraindications or administration recommendations.

E. Suspension or withdrawal

Where evidence demonstrates an unacceptable safety concern, appropriate regulatory measures may include restricting, suspending or withdrawing authorization.

F. Compensation

Individuals suffering vaccine-related injuries may seek remedies under applicable legal principles, depending on causation, responsibility and the circumstances of administration.

9. Case Laws and Judicial Decisions

Moroccan vaccine litigation is particularly important because it demonstrates how courts may examine the relationship between public health administration and individual rights.

There is a distinction between judicial decisions directly concerning vaccine injuries and decisions interpreting the regulatory authorization process itself. The following reported litigation concerns the former.

Case 1. Administrative Court of Rabat – AstraZeneca Vaccine Injury Case (2024)

Important Moroccan decision

Background

In a case filed in June 2022, a woman alleged that she suffered facial paralysis and paralysis affecting her lower limbs following administration of the AstraZeneca COVID-19 vaccine.

She brought proceedings against the Moroccan Ministry of Health.

In February 2024, the Administrative Court of Rabat ordered the government to pay MAD 250,000 in compensation.

Legal reasoning at first instance

According to contemporary reporting, the court considered the state's responsibility for injuries associated with vaccination.

The reasoning reportedly emphasized that the government had a duty to protect citizens against risks associated with vaccines it had authorized and promoted.

The court considered whether state responsibility could arise without the claimant having to establish administrative fault.

Legal significance

The decision raised important questions about:

State responsibility for vaccine-related injuries.

Government authorization of pharmaceutical products.

Public health administration.

Causation and medical evidence.

Compensation for injuries following vaccination.

Important qualification: The decision was subsequently overturned on appeal. Therefore, the first-instance reasoning cannot be presented as the final legal position.

Sources:

Hespress Français - Actualités du Maroc+1

Case 2. Rabat Administrative Court of Appeal – 24 July 2024

Background

The Moroccan government appealed the first-instance compensation decision.

On 24 July 2024, the Administrative Court of Appeal in Rabat overturned the judgment that had ordered payment of MAD 250,000.

The appeal court dismissed the claimant's compensation claim.

Legal significance

This decision is important because it demonstrates that the initial recognition of state responsibility for an alleged vaccine injury did not survive appellate review.

It also highlights the importance of:

Medical evidence.

Establishing causation.

Applicable administrative liability principles.

Appellate judicial scrutiny.

The distinction between vaccine authorization and automatic government liability.

The full text and detailed reasoning of the appellate judgment were not available in the contemporaneous reporting consulted. Consequently, it would be inappropriate to invent a specific legal test or declare that the appellate court definitively rejected strict liability as a general doctrine.

Source:

Numéro un de l'information économique marocaine+1

Case 3. European Court of Human Rights – Vavřička and Others v. Czech Republic (2021)

Citation: Applications Nos. 47621/13 and others, Grand Chamber, judgment of 8 April 2021.

Although this is not a Moroccan case, it provides a useful comparative precedent.

Background

The applicants challenged compulsory childhood vaccination requirements in the Czech Republic.

Legal issue

Whether compulsory vaccination policies violated Article 8 of the European Convention on Human Rights, which protects private and family life.

Judgment

The European Court held that the Czech vaccination framework did not violate Article 8 in the circumstances of the case.

Relevance to Morocco

The judgment provides comparative guidance on:

Public health protection.

Individual autonomy.

Proportionality.

Vaccine safety.

State regulatory discretion.

It is not binding Moroccan precedent, but its reasoning may be useful in comparative legal scholarship.

Case 4. European Court of Human Rights – Solomakhin v. Ukraine (2012)

Citation: Application No. 24429/03, judgment of 15 March 2012.

Background

The applicant challenged the administration of a vaccination and alleged that it had affected his health.

Legal issue

Whether vaccination constituted an interference with the right to private life under Article 8.

Judgment

The Court recognized that medical intervention without consent can engage Article 8. It nevertheless accepted that vaccination may be justified where it protects public health, provided that the relevant safeguards and proportionality requirements are respected.

Relevance to Morocco

The case offers comparative guidance on:

Informed consent.

Medical intervention.

Individual bodily integrity.

Public health interests.

Government responsibility for vaccination programmes.

It is persuasive comparative material, not binding Moroccan law.

10. Legal Liability in Vaccine Development and Approval

Vaccine regulation involves several categories of legal responsibility.

A. Manufacturer Liability

A manufacturer may face legal consequences where a vaccine is defective, improperly manufactured or does not comply with applicable quality requirements.

B. Clinical-Trial Sponsor Liability

Article 34 of Law No. 28-13 provides an important statutory basis for compensation where damage to a participant is causally connected to biomedical research.

C. Government Liability

Government liability may arise where the requirements of applicable administrative responsibility principles are satisfied.

The 2024 AstraZeneca litigation demonstrates that the issue is legally contested and that a first-instance compensation judgment must not be treated as conclusive after being overturned on appeal.

D. Regulatory Accountability

Regulatory authorities must exercise their statutory powers lawfully and reasonably.

Potential legal issues include:

Unlawful authorization.

Failure to observe mandatory procedures.

Inadequate regulatory supervision.

Failure to respond appropriately to safety information.

Improper suspension or withdrawal of authorization.

11. International Legal Framework

Morocco's vaccine regulatory system also operates within an international public health environment.

Important international instruments and standards include:

WHO vaccine regulatory standards: Guidance on vaccine quality, safety, efficacy and regulatory oversight.

International Council for Harmonisation (ICH): Technical standards relevant to clinical research and pharmaceutical quality.

Good Clinical Practice: Standards for protecting participants and ensuring reliable clinical-trial data.

Good Manufacturing Practice: Requirements governing pharmaceutical manufacturing.

International Health Regulations (2005): International cooperation concerning public health emergencies.

UNICEF procurement standards: Relevant to international vaccine procurement and the special batch-release exemption under Moroccan law.

These international standards support regulatory harmonization but do not automatically replace Moroccan domestic authorization requirements.

12. Major Regulatory Challenges in Morocco

A. Scientific Evidence and Accelerated Approval

The main challenge is balancing rapid vaccine availability with sufficient scientific evidence.

An emergency must not become an excuse for abandoning safety standards.

B. Limited Domestic Manufacturing Capacity

Developing domestic vaccine manufacturing requires:

Technology transfer.

Qualified laboratories.

Skilled personnel.

Advanced production facilities.

Reliable supply chains.

Independent quality-control systems.

C. Clinical Research Protection

Emergency research must protect participants against coercion, inadequate consent and unjustified exposure to risks.

D. Regulatory Independence

Regulatory decisions should be based on scientific evidence rather than commercial or political pressure.

E. Compensation Mechanisms

Morocco's reported AstraZeneca litigation demonstrates the importance of clear legal rules concerning vaccine-related injury, causation and compensation.

F. Transparency

Regulatory institutions should provide appropriate public information about:

Vaccine authorization.

Clinical-trial results.

Safety findings.

Batch-release decisions.

Adverse-event monitoring.

Changes to vaccine recommendations.

13. Suggested Legal Reforms

Morocco could further strengthen vaccine governance through the following measures.

1. Comprehensive emergency authorization legislation

Establish clear statutory requirements for emergency marketing authorization, including eligibility, decision-making criteria and review procedures.

2. Defined emergency review timelines

Introduce transparent timelines for emergency applications while preserving scientific and ethical review.

3. Conditional authorization safeguards

Establish legally defined obligations for additional evidence, periodic reassessment and withdrawal where necessary.

4. Independent scientific review

Strengthen the institutional independence and technical capacity of vaccine assessment committees.

5. Vaccine injury compensation framework

Consider a clearly defined no-fault compensation mechanism for qualifying vaccine injuries, with transparent eligibility, medical assessment and appeal procedures.

6. Improved pharmacovigilance

Strengthen adverse-event reporting, safety databases and communication between hospitals, manufacturers and regulatory authorities.

7. International regulatory cooperation

Improve cooperation with WHO and other national regulatory authorities for scientific information exchange and vaccine quality assessment.

8. Domestic vaccine innovation

Encourage research partnerships between universities, biotechnology companies and public institutions while maintaining appropriate intellectual property, biosafety and quality standards.

14. Conclusion

Morocco's regulation of vaccine development and emergency approval pathways rests principally on Law No. 17-04, Law No. 28-13, pharmaceutical implementing regulations and the institutional framework of the AMMPS.

Three developments are particularly significant:

The 2015 biomedical research legislation established safeguards for clinical-trial participants.

The 2024 pharmaceutical reform introduced mandatory official batch-release certification for relevant vaccines and sera.

The AMMPS's April 2026 emergency clinical-trial guidelines introduced a more structured approach to accelerated biomedical research during health emergencies.

The AstraZeneca litigation of 2024 further illustrates the importance of judicial supervision and legal accountability in vaccination programmes.

Ultimately, the central legal objective is to balance three competing considerations: scientific innovation, rapid public health protection and individual rights.

Morocco's future vaccine regulatory framework will benefit from clearer emergency marketing authorization rules, stronger pharmacovigilance, transparent regulatory decisions and effective compensation arrangements.

15. Important Legal Sources and Research References

Primary research sources:

WIPO – Moroccan Law No. 17-04.

Moroccan Law No. 28-13 – Biomedical Research.

Official Bulletin – 2024 Vaccine Regulatory Reform.

AMMPS – Emergency Clinical-Trial Guidelines, 2026.

Institut Pasteur du Maroc – Vaccine Production.

Moroccan AstraZeneca Compensation Appeal, 2024.

Academic qualification: The two reported Moroccan AstraZeneca decisions are particularly relevant domestic judicial authorities. The other cases discussed above are comparative foreign precedents. The available materials do not establish a substantial body of reported Moroccan judgments directly interpreting emergency vaccine marketing authorization. The distinction between enacted legislation, administrative guidance and judicial precedent is therefore essential when citing this subject in academic or legal research.